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Demographics	 	 	 	 	 	
Age	years,	Median	(IQR)	 74	(66-80)	 69	(62-77)	 65	(58-72)	 64	(56-72)	 <0.0001	
Age	≥75	years,	n	(%)	 453	(47.7)	 276	(32.5)	 85	(16.0)	 21	(18.3)	 <0.0001	
Female	Gender,	n	(%)	 462	(48.7)	 349	(41.2)	 140	(26.4)	 28	(24.3)	 <0.0001	
BMI,	n	(%)	2,389	 	 	 	 	 0.008	
Underweight	 16	(1.7)	 9	(1.1)	 2	(0.4)	 0	 	
Normal	 271	(29.6)	 216	(25.8)	 145	(27.7)	 40	(35.4)	 	
Overweight	 373	(40.7)	 348	(41.6)	 235	(44.9)	 54	(47.8)	 	
Obese	 257	(28.0)	 263	(31.5)	 141	(27.0)	 19	(16.8)	 	
LVEF	%,	Mean±SD	 52.5±14.4	 52.0±13.0	 52.6±13.0	 55.8±12.2	 0.0420	
AF	Subtypes,	n	(%)	2,403	 	 	 	 	 <0.0001	
First	Detected	 311	(33.1)	 235	(28.4)	 169	(32.4)	 25	(21.9)	 	
Paroxysmal	 202	(21.5)	 240	(29.0)	 146	(28.0)	 44	(38.6)	 	
Long-Standing	Persistent	 32	(3.4)	 55	(6.6)	 16	(3.1)	 6	(5.3)	 	
Persistent	 175	(18.6)	 173	(20.9)	 126	(24.1)	 21	(18.4)	 	
Permanent	 219	(23.3)	 125	(15.1)	 65	(12.5)	 18	(15.8)	 	
Cardiovascular	Risk	Factors,	n	(%)	 	 	 	 	 	
Diabetes	Mellitus	2,430	 226	(24.0)	 178	(21.1)	 77	(14.6)	 15	(13.2)	 <0.0001	
Hypertension	2,431	 694	(73.5)	 643	(76.1)	 335	(63.3)	 57	(50.4)	 <0.0001	












Hypercholesterolemia	2,398	 466	(50.2)	 423	(50.7)	 230	(43.9)	 45	(40.5)	 0.019	
Alcohol	≥2-3	units/day	2,356	 64	(7.0)	 59	(7.2)	 56	(11.0)	 14	(13.0)	 0.010	
Concomitant	Conditions,	n	(%)	 	 	 	 	 	
Coronary	Artery	Disease	2,117	 329	(39.2)	 271	(37.3)	 145	(31.8)	 22	(23.2)	 0.0024	
Chronic	Heart	Failure	2,324	 453	(49.0)	 416	(51.1)	 200	(41.4)	 28	(27.2)	 <0.0001	
Valvular	Heart	Disease	2,299	 620	(67.9)	 524	(64.9)	 282	(58.4)	 52	(54.2)	 0.0007	
Dilated	Cardiomyopathy	2,311	 106	(11.5)	 107	(13.2)	 50	(10.4)	 5	(5.0)	 0.0750	
HCM	2,315	 32	(3.5)	 39	(4.8)	 18	(3.7)	 3	(3.0)	 0.5125	
Previous	Stroke	2,429	 77	(8.1)	 53	(6.3)	 15	(2.9)	 6	(5.3)	 0.0010	
Previous	TIA	2,421	 48	(5.1)	 29	(3.5)	 17	(3.2)	 5	(4.4)	 0.2363	
PVD	2,310	 130	(14.0)	 88	(11.2)	 58	(11.7)	 6	(5.9)	 0.0610	
CHA2DS2-VASc	score	 	 	 	 	 	
Mean	score	±	SD	 3.79	±1.74	 3.31	±1.73	 2.44	±1.68	 2.17	±1.78	 <0.0001	
CHA2DS2-VASc	class,	n	(%)	 	 	 	 	 <0.0001	
Class	0	 22	(5.8)	 35	(4.1)	 65	(12.3)	 19	(16.5)	 	
Class	1	 76	(8.0)	 103	(12.1)	 101	(19.1)	 29	(25.2)	 	






























	 	 	 	 	
Antithrombotic	therapy,	n	(%)	 	 	 	 	 	
At	least	one	2,438	 911	(96.1)	 823	(97.2)	 498	(94.3)	 110	(95.7)	 0.071	
Antiplatelet	2,438	 296	(31.2)	 312	(36.8)	 179	(33.9)	 30	(26.1)	 0.025	
Oral	anticoagulant	2,437	 761	(80.4)	 697	(82.3)	 430	(81.4)	 97	(84.3)	 0.619	
NOACs	2,439	 63	(6.6)	 60	(7.1)	 45	(8.5)	 18	(15.7)	 0.005	
Antiarrhythmic	drugs,	n	(%)	2,441	 	 	 	 	 	
At	least	one	 289	(30.5)	 306	(36.1)	 215	(40.6)	 45	(39.1)	 <0.001	
Antiarrhythmic	Class	I	 73	(7.7)	 80	(9.4)	 68	(12.8)	 19	(16.5)	 0.001	
Antiarrhythmic	Class	III	 217	(22.9)	 224	(26.4)	 152	(28.7)	 26	(22.6)	 0.066	
Other	treatments,	n	(%)	 	 	 	 	 	
Statins	2,437	 443	(46.7)	 453	(53.5)	 243	(46.1)	 45	(39.1)	 0.002	
ACEi/ARBs	2,438	 609	(64.4)	 587	(69.3)	 324	(61.1)	 60	(52.2)	 <0.001	
Beta	blockers	2,437	 637	(67.3)	 611	(72.2)	 379	(71.5)	 76	(66.1)	 0.0870	
Diuretics	2,439	 564	(59.6)	 458	(54.1)	 221	(41.7)	 30	(26.1)	 <0.0001	
Aldosterone	blockers	2,439	 269	(28.4)	 209	(24.7)	 121	(22.8)	 12	(10.4)	 <0.001	
DHP	calcium-channel	blockers	
2,439	
118	(12.4)	 125	(14.8)	 75	(14.2)	 7	(6.1)	 0.053	
Non-DHP	calcium-channel	
blockers	2,439	












Digoxin	2,440	 208	(21.9)	 169	(20.0)	 86	(16.2)	 12	(10.4)	 0.004	
DRI	Aliskiren	2,439	 2	(0.2)	 0	 2	(0.4)	 0	 0.358*	
Oral	anti-diabetics	2,441	 157	(16.5)	 121	(14.3)	 59	(11.1)	 10	(8.7)	 0.011	
Insulin	2,441	 58	(6.1)	 44	(5.2)	 17	(3.2)	 4	(3.5)	 0.085	
Thyroid-suppressing	drugs	
2,441	
22	(2.3)	 17	(2.0)	 16	(3.0)	 6	(5.2)	 0.169	
Beta-2	agonists	2,441	 21	(2.2)	 11	(1.3)	 6	(1.1)	 1	(0.9)	 0.274	

















Pharmacological	Cardioversion	 52	(6.3%)	 78	(9.6)	 58	(11.2)	 17	(15.3)	 0.0013	
Electrical	Cardioversion	 32	(4.0)	 30	(3.8)	 34	(6.8)	 14	(12.8)	 <0.0001	








































































































































Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 9	(1.1%)	 9	(1.2%)	 2	(0.4%)	 1	(1.0%)	 0.426*	
Bleeding	 13	(1.7%)	 9	(1.2%)	 3	(0.6%)	 0	 0.235*	
Any	TE	 34	(4.3%)	 25	(3.4%)	 21	(4.2%)	 3	(2.9%)	 0.733*	
CV	death	 53	(5.8%)	 12	(1.4%)	 2	(0.4%)	 1	(0.9%)	 <0.0001*	
All-cause	death	 116	(12.2%)	 33	(3.9%)	 7	(1.3%)	 3	(2.6%)	 <0.0001*	
All-cause	death/Any	TE	 150	(16.6%)	 58	(7.5%)	 28	(5.5%)	 6	(5.6%)	 <0.0001	







	 	 Odds	Ratio*	 95%	CI	 p	
Occasional	 Stroke/TIA	 1.07	 [0.42-2.71]	 0.885	
	 Any	TE	 0.78	 [0.46-1.32]	 0.353	
	 Bleeding	 0.72	 [0.51-1.03]	 0.07	
	 CV	death/Any	TE/Bleeding	 0.48	 [0.33-0.69]	 <0.0001	
Regular	 Stroke/TIA	 0.35	 [0.07-1.62]	 0.159	
	 Any	TE	 0.97	 [0.56-1.70]	 0.923	
	 Bleeding	 0.75	 [0.47-1.19]	 0.218	
	 CV	death/Any	TE/Bleeding	 0.40	 [0.26-0.63]	 <0.0001	
Intense	 Stroke/TIA	 0.83	 [0.10-6.65]	 0.864	
	 Any	TE	 0.65	 [0.20-2.17]	 0.484	
	 Bleeding	 0.49	 [0.17-1.37]	 0.169	





































Demographics	 	 	 	
Age	in	years	Median	(IQR)	 70	(62-76)	 66	(59-74)	 0.023	
Age	≥75	years,	n	(%)	 29	/	88	(33.0)	 120	/	515	(23.3)	 0.052	
Female	gender,	n	(%)	 36	/	88	(40.9)	 218	/	515	(42.3)	 0.803	
BMI,	n	(%)	 	 	 0.008	
Underweight	 3	/	86	(3.5)	 1	/	507	(0.2%)	 	
Normal	 30	/	86	(34.9)	 134	/	507	(26.4%)	 	
Overweight	 35	/	86	(40.7)	 233	/	507	(46.0%)	 	
Obese	 18	/	86	(20.9)	 139	/	507	(27.4%)	 	
Cardiovascular	Risk	Factors,	n	(%)	 	 	 	
Diabetes	Mellitus	 10	/	88	(11.4)	 86	/	512	(16.8)	 0.199	
Hypertension	 65	/	88	(73.9)	 355	/	514	(69.1)	 0.365	
Current	Smoker	 12	/	86	(14.0)	 65	/	508	(12.8)	 0.767	
Hypercholesterolemia	 45	/	86	(52.3)	 234	/	510	(45.9)	 0.268	
Alcohol	≥2-3	units/day	 6	/	86	(7.0)	 24	/	503	(4.8)	 0.423*	
CHA2DS2-VASc	score	 	 	 0.306	
Mean	score	±	SD	 2.9	±1.6	 2.7	±1.8	 	
CHA2DS2-VASc	class,	n	(%)	 	 	 0.025	
Class	0	 6	/	88	(6.8)	 45	/	515	(8.7)	 	












Antithrombotic	Therapy,	n	(%)	 	 	 	
At	least	one	 84	/	88	(95.5)	 490	/	515	(95.1)	 >0.999	
Antiplatelet	 19	/	88	(21.6)	 178	/	514	(34.6)	 0.016	
Oral	anticoagulant	 75	/	88	(85.2)	 397	/	514	(77.2)	 0.092	
NOACs	 5	/	88	(5.7)	 39	/	515	(7.6)	 0.529	
Antiarrhythmic	Drugs,	n	(%)	 	 	 	
At	least	one	 45	/	88	(51.1)	 252	/	515	(48.9)	 0.702	
Antiarrhythmic	class	I	 15	/	88	(17.0)	 98	/	515	(19.0)	 0.659	
Antiarrhythmic	class	III	 29	/	88	(33.0)	 155	/	515	(30.1)	 0.591	
Other	Treatments,	n	(%)	 	 	 	
Statins	 46	/	88	(52.3)	 259	/	514	(50.4)	 0.744	
ACEi/ARBs	 63	/	88	(71.6)	 317	/	512	(61.9)	 0.082	
Beta	blockers	 58	/	88	(65.9)	 352	/	514	(68.5)	 0.632	
Diuretics	 33	/	88	(37.5)	 185	/	514	(36.0)	 0.786	
Aldosterone	blockers	 10	/	88	(11.4)	 55	/	514	(10.7)	 0.853	
DHP	calcium-channel	blockers	 11	/	88	(12.5)	 76	/	514	(14.8)	 0.573	
Non-DHP	calcium-channel	blockers	 5	/	88	(5.7)	 21	/	514	(4.1)	 0.567*	








Oral	anti-diabetics	 8	/	88	(9.1)	 61	/	515	(11.8)	 0.453	
Insulin	 2	/	88	(2.3)	 18	/	515	(3.5)	 0.753*	
Thyroid-suppressing	drugs	 4	/	88	(4.5)	 11	/	515	(2.1)	 0.254*	
Beta-2	agonists	 -	 2	/	515	(0.4)	 >0.999*	









	 None	 Occasional	 Regular	 Intense	 p	
Male	Patients	 	 	 	 	 	
N°	of	patients	 487	 499	 390	 87	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 4	(1.0%)	 4	(0.9%)	 2	(0.5%)	 1	(1.2%)	 0.750	
Bleeding	 8	(2.0%)	 6	(1.4%)	 2	(0.5%)	 0	 0.277	
Any	TE	 15	(3.7%)	 16	(3.7%)	 20	(5.3%)	 2	(2.5%)	 0.497	
CV	death	 28	(6.0%)	 9	(1.8%)	 1	(0.3%)	 1	(1.2%)	 <0.0001	
All-cause	death	 65	(13.3%)	 24	(4.8%)	 4	(1.0%)	 2	(2.3%)	 <0.0001	
All-cause	death	/Any	TE	 80	(17.0%)	 40	(8.7%)	 24	(6.3%)	 4	(4.8%)	 <0.0001	
CV	death/Any	TE/Bleeding	 51	(12.0%)	 30	(6.9%)	 23	(6.2%)	 3	(3.7%)	 0.004	
	 	 	 	 	 	
Female	Patients	 	 	 	 	 	
N°	of	patients	 462	 349	 140	 28	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 5	(1.3%)	 5	(1.6%)	 0	 0	 0.611	
Bleeding	 5	(1.3%)	 3	(1.0%)	 1	(0.8%)	 0	 0.927	
Any	TE	 19	(4.9%)	 9	(3.0%)	 1	(0.8%)	 1	(4.2%)	 0.110	
CV	death	 25	(5.6%)	 3	(0.9%)	 1	(0.7%)	 0	 <0.001	
All-cause	death	 51	(11.0%)	 9	(2.6%)	 3	(2.1%)	 1	(3.6%)	 <0.0001	
All-cause	death/Any	TE	 70	(16.1%)	 18	(5.8%)	 4	(3.1%)	 2	(8.0%)	 <0.0001	
CV	death/Any	TE/Bleeding	 48	(12.0%)	 15	(4.9%)	 3	(2.4%)	 1	(4.2%)	 <0.001	
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Elderly	Patients	 	 	 	 	 	
N°	of	patients	 453	 276	 85	 21	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 7	(1.9%)	 3	(1.3%)	 0	 0	 0.749	
Bleeding	 8	(2.2%)	 3	(1.3%)	 0	 0	 0.693	
Any	TE	 17	(4.7%)	 7	(3.0%)	 5	(6.4%)	 1	(5.3%)	 0.451	
CV	death	 30	(7.0%)	 4	(1.5%)	 1	(1.2%)	 0	 0.002	
All-cause	death	 74	(16.3%)	 17	(6.2%)	 3	(3.5%)	 1	(4.8%)	 <0.0001	
All-cause	death/Any	TE	 91	(20.9%)	 24	(9.7%)	 8	(9.9%)	 2	(10.0%)	 <0.001	
CV	death/Any	TE/Bleeding	 54	(14.0%)	 16	(7.0%)	 6	(7.8%)	 1	(5.3%)	 0.032	
	 	 	 	 	 	
Paroxysmal	AF	 	 	 	 	 	
N°	of	patients	 202	 240	 146	 44	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 2	(1.2%)	 1	(0.4%)	 0	 0	 0.590	
Bleeding	 1	(0.6%)	 0	 1	(0.7%)	 0	 0.433	
Any	TE	 9	(5.3%)	 5	(2.2%)	 7	(4.9%)	 0	 0.179	
CV	death	 11	(5.6%)	 1	(0.4%)	 0	 0	 <0.001	
All-cause	death	 20	(9.9%)	 4	(1.7%)	 1	(0.7%)	 0	 <0.0001	
All-cause	death/Any	TE	 29	(15.3%)	 9	(4.0%)	 8	(5.6%)	 0	 <0.0001	
CV	death/Any	TE/Bleeding	 21	(11.8%)	 6	(2.7%)	 8	(5.6%)	 0	 <0.001	
	 	 	 	 	 	
High	Risk	(CHA2DS2-VASc≥2)	 	 	 	 	 	
N°	of	patients	 851	 710	 364	 67	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
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	 None	 Occasional	 Regular	 Intense	 p	
Stroke/TIA	 9	(1.3%)	 8	(1.3%)	 2	(0.6%)	 1	(1.8%)	 0.575	
Bleeding	 11	(1.6%)	 9	(1.5%)	 3	(0.9%)	 0	 0.819	
Any	TE	 32	(4.6%)	 23	(3.8%)	 18	(5.4%)	 3	(5.3%)	 0.723	
CV	death	 51	(6.3%)	 11	(1.6%)	 2	(0.6%)	 1	(1.5%)	 <0.0001	
All-cause	death	 114	(13.4%)	 32	(4.5%)	 6	(1.6%)	 3	(4.5%)	 <0.0001	
All-cause	death/Any	TE	 146	(18.0%)	 55	(8.7%)	 24	(7.0%)	 6	(10.0%)	 <0.0001	
CV	death/Any	TE/Bleeding	 93	(12.7%)	 42	(7.0%)	 23	(6.9%)	 4	(6.9%)	 <0.001	
Legend:	CV=	cardiovascular;	TE=	thromboembolic	event;	TIA=	transient	ischemic	attack.
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	 Table	S3:	M
ultivariable	Effect	of	Physical	Activity	on	M
ajor	Adverse	Events	According	to	Subgroups	
PA	
1-year	O
utcom
e	
M
ale	Patients	
Fem
ale	Patients	
Elderly	Patients	
	
	
O
R*	
95%
	CI	
p	
O
R*	
95%
	CI	
p	
O
R*	
95%
	CI	
p	
O
ccasional	
Stroke/TIA	
0.93	
[0.23-3.75]	
0.922	
1.27	
[0.36-4.43]	
0.706	
0.66	
[0.17-2.60]	
0.555	
	
Any	TE	
0.99	
[0.48-2.04]	
0.990	
0.59	
[0.26-1.32]	
0.193	
0.63	
[0.26-1.55]	
0.321	
	
Bleeding	
0.67	
[0.41-1.10]	
0.109	
0.78	
[0.47-1.31]	
0.346	
0.45	
[0.26-0.76]	
0.003	
	
CV	death/	
Any	TE/Bleeding	
0.55	
[0.34-0.88]	
0.011	
0.38	
[0.21-0.69]	
0.001	
0.46	
[0.26-0.83]	
0.008	
Regular	
Stroke/TIA	
0.54	
[0.10-2.96]	
0.470	
NA	
NA	
-	
NA	
NA	
-	
	
Any	TE	
1.47	
[0.74-2.91]	
0.269	
0.15	
[0.02-1.15]	
0.036	
1.39	
[0.49-3.88]	
0.215	
	
Bleeding	
0.65	
[0.35-1.21]	
0.177	
0.93	
[0.45-1.90]	
0.840	
0.91	
[0.36-2.27]	
0.532	
	
CV	death/	
Any	TE/Bleeding	
0.48	
[0.29-0.81]	
0.005	
0.18	
[0.05-0.58]	
0.001	
0.52	
[0.21-1.25]	
0.139	
Intense	
Stroke/TIA	
1.25	
[0.14-11.36]	
0.841	
NA	
NA	
-	
NA	
NA	
-	
	
Any	TE	
0.66	
[0.15-2.94]	
0.581	
0.84	
[0.11-6.54]	
0.866	
1.12	
[0.14-8.92]	
0.912	
	
Bleeding	
0.34	
[0.08-1.46]	
0.131	
0.99	
[0.23-4.36]	
0.993	
0.73	
[0.09-5.56]	
0.761	
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	 PA	
1-year	O
utcom
e	
M
ale	Patients	
Fem
ale	Patients	
Elderly	Patients	
	
CV	death/	
Any	TE/Bleeding	
0.28	
[0.08-0.92]	
0.025	
0.32	
[0.04-2.41]	
0.244	
0.34	
[0.04-2.61]	
0.278	
Legend:	*Analysis	presented	is	unadjusted	univariate	logistic	analysis.	CI=	confidence	interval;	CV=	cardiovascular;	NA=	not	available;	OR=	odds	
ratio;	TE=	throm
boem
bolism
;	TIA=	transient	ischem
ic	attack.	
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	 Table	S3	(Continued):	M
ultivariable	Effect	of	Physical	Activity	on	M
ajor	Adverse	Events	According	to	Subgroups	
PA	
1-year	O
utcom
e	
Paroxysm
al	AF	
High	Risk	(CHA
2 DS
2 -VASc≥2)	
	
	
O
R*	
95%
	CI	
p	
O
R*	
95%
	CI	
p	
O
ccasional	
Stroke/TIA	
0.38	
[0.03-4.18]	
0.408	
1.03	
[0.39-2.68]	
0.953	
	
Any	TE	
0.41	
[0.13-1.24]	
0.103	
0.82	
[0.48-1.43]	
0.491	
	
Bleeding	
0.58	
[0.25-1.35]	
0.200	
0.64	
[0.44-0.92]	
0.017	
	
CV	death/	
Any	TE/Bleeding	
0.21	
[0.08-0.52]	
<0.001	
0.51	
[0.35-0.75]	
<0.001	
Regular	
Stroke/TIA	
NA	
NA	
-	
0.46	
[0.10-2.13]	
0.308	
	
Any	TE	
0.92	
[0.33-2.54]	
0.875	
1.18	
[0.65-2.13]	
0.588	
	
Bleeding	
2.73	
[0.87-8.57]	
0.074	
0.96	
[0.60-1.55]	
0.975	
	
CV	death/	
Any	TE/Bleeding	
0.45	
[0.19-1.04]	
0.056	
0.51	
[0.31-0.82]	
0.005	
Intense	
Stroke/TIA	
-	
-	
-	
1.37	
[0.17-10.98]	
0.768	
	
Any	TE	
-	
-	
-	
1.16	
[0.34-3.90]	
0.815	
	
Bleeding	
-	
-	
-	
0.85	
[0.30-2.43]	
0.771	
11	
	 PA	
1-year	O
utcom
e	
Paroxysm
al	AF	
High	Risk	(CHA
2 DS
2 -VASc≥2)	
	
CV	death/	
Any	TE/Bleeding	
-	
-	
-	
0.51	
[0.18-1.44]	
0.196	
Legend:	*Analysis	presented	is	unadjusted	univariate	logistic	analysis.	CI=	confidence	interval;	CV=	cardiovascular;	NA=	not	available;	OR=	odds	
ratio;	TE=	throm
boem
bolism
;	TIA=	transient	ischem
ic	attack.	
